Morristown, N.J. – September 16, 2026 -- Whitehawk Therapeutics (Nasdaq: WHWK) presented real-world data at the IASLC 2026 World Conference on Lung Cancer in Seoul showing that PTK7 expression remains stable in pretreated, EGFR wild-type non-small cell lung cancer (NSCLC), reinforcing the target biology behind its Phase 1 antibody-drug conjugate (ADC) HWK-007.
Suzhou – September 13, 2026 -- Transcenta Therapeutics has licensed its Highly Intensified Continuous Bioprocessing (HiCB) platform to WuXi Biologics under a non-exclusive technology agreement, securing an upfront payment of RMB 10 million plus future milestone payments.
Under the deal, Transcenta and its subsidiary HJB will license certain technologies tied to the HiCB continuous bioprocessing platform and its ExcelPro cell culture media to WuXi Biologics and its affiliates. WuXi Biologics will become a strategic CMC development partner supporting molecules across Transcenta's pipeline.